Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clearmind Medicine Inc.'s SEC filings document foreign private issuer reports for a clinical-stage biotech developing non-hallucinogenic, neuroplastogen-derived psychedelic therapeutics. Form 6-K reports furnish press releases on CMND-100, MEAI-based Alcohol Use Disorder clinical development, European patent activity for PTSD compounds, and communications tied to FDA regulatory pathways.
The filings also record capital-structure matters, including securities purchase agreements, convertible promissory notes, conversions into common shares and amendments to financing capacity. Governance disclosures cover board composition, committee assignments and Nasdaq independence determinations, while incorporated registration statements on Form F-3 and Form S-8 connect current reports to the company's securities registration record.
Clearmind Medicine Inc. entered a conversion agreement with two existing investors, allowing each to convert $600,000 of outstanding convertible notes into common shares at a fixed price of $0.30 per share. This follows earlier note issuances under securities purchase agreements that permit up to $10 million in aggregate principal.
The agreement temporarily overrides the usual conversion formula for this $600,000 per investor and formally resets the floor price in the note form to $0.30 per share. The resulting conversion shares are already covered by an effective resale registration statement and will be issued electronically without restrictive legends, giving the investors freely tradable stock while reducing Clearmind’s convertible note balance.
Clearmind Medicine Inc. is implementing a 1-for-10 reverse share split of its common shares to support its plan to regain compliance with the Nasdaq Minimum Bid Price Rule. The reverse split will be effective and the shares will begin trading on this basis on May 21, 2026.
After the reverse split, issued and outstanding common shares will be adjusted from 10,190,337 to approximately 1,019,033, while authorized share capital will remain unlimited. Fractional shares will not be issued and will instead be rounded up to the nearest whole share, and all outstanding options and warrants will be proportionately adjusted.
Clearmind Medicine Inc. reports a new funding step under its existing convertible loan arrangement. The company agreed with its CLA investors to issue and sell convertible promissory notes with an aggregate principal amount of $600,000, as part of a broader facility of up to $10,000,000 established under amended securities purchase agreements from September 17, 2025.
The CLA investors will pay an aggregate cash purchase price equal to 90% of the notes’ principal, or $540,000, providing discounted financing to the company. The transaction is expected to close on or about May 19, 2026. This report is also incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.
Clearmind Medicine Inc. has signed a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to study its compound MEAI (CMND-100) alongside tirzepatide in diet-induced obese mice. The 12‑month preclinical study will test MEAI both in combination with tirzepatide and as a maintenance therapy after tirzepatide treatment to assess weight regain and metabolic effects.
Earlier work with the same laboratory showed MEAI produced about 15–20% body weight reduction in obese mice, mainly by increasing energy expenditure and fat use while preserving lean mass. Clearmind positions MEAI as a non‑hallucinogenic, second‑generation neuroplastogen that could complement GLP‑1–based obesity therapies in a market estimated at $50–66 billion in 2025 and projected to reach $170–185 billion by 2033. The company also highlights an intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc. amended a Schedule 13G/A reporting that L.I.A. Pure Capital Ltd. holds five percent or less of the company’s common shares as of 03/31/2026. The filing identifies the reporting person, its Israel address, and CUSIP 185053402.
Clearmind Medicine Inc. receiving a Schedule 13G/A amendment from Capitalink Ltd. reports ownership of 5 percent or less of the class of Common Shares (CUSIP 185053402).
The amendment (Amendment No. 3) lists Capitalink Ltd., an Israel entity, as the reporting person and incorporates cover-page items for detailed voting and dispositive power. The filing is signed by Lavi Krasney as CEO on 05/15/2026.
Clearmind Medicine Inc. filed a Form 6-K highlighting a clinical milestone in its Phase I/IIa trial of CMND-100 (MEAI) for moderate to severe alcohol use disorder. The company has now treated 20 participants across all cohorts, after dosing two additional patients in the fourth cohort.
The fourth cohort is receiving a higher 160 mg dose of CMND-100, following a positive recommendation from the Data and Safety Monitoring Board and successful completion of the third cohort in April 2026. The first three cohorts, totaling 18 participants, met the primary safety endpoint with no serious adverse events reported, supporting continued dose escalation.
The ongoing FDA-approved trial is a multinational, multicenter study assessing safety, tolerability, pharmacokinetics and preliminary efficacy at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens biotech with 19 patent families and 31 granted patents, focused on non-hallucinogenic treatments for under-served conditions such as alcohol use disorder.
Clearmind Medicine Inc. has filed a European patent application covering novel psychedelic compounds aimed at treating Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The application is part of its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
Clearmind holds exclusive global rights under this agreement to develop, manufacture, and commercialize Yissum-derived compounds and is responsible for advancing them through regulatory pathways. The company describes itself as a clinical-stage biotech focused on non-hallucinogenic, second generation, neuroplastogen-derived therapeutics for under-treated conditions such as alcohol use disorder.
The PTSD treatment market is cited at about $18.5 billion in 2025, projected to reach $30.2 billion by 2035, a 5.0% CAGR, highlighting the commercial potential of effective therapies. Clearmind’s intellectual property portfolio currently consists of nineteen patent families, including thirty-one granted patents, and the company plans to pursue additional protections where warranted.
Clearmind Medicine Inc. files a Form F-3 to register for resale up to 22,626,988 common shares that are issued or issuable upon conversion of convertible promissory notes held by institutional investors (the CLA Investors). The registered shares are calculated assuming conversion of up to $10.0M principal plus $3.576M accrued interest at an assumed conversion price of $0.60 per share.
The company has received $8.15M in gross proceeds from Promissory Notes to date and may receive up to an additional $10.0M of gross proceeds under the SPAs. Conversion terms provide that the conversion price is the lower of a $40.40 fixed price or 88% of the 20-day VWAP, subject to a $0.60 Floor Price (amended). CLA Investor conversions are limited so no single CLA Investor exceeds 4.99% beneficial ownership following conversion.